This drug activates CD8 T cells in the tumor microenvironment and has potential alone or in combination with PD-1/PD-L1 mAb for the treatment of advanced solid tumors, especially for CLDN18.2-positive pancreatic ductal adenocarcinoma. Here, CD274 is linked to neoplasm.